Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Stability-Indicating Method for Lyophilized Injections – V 2.0

Posted on By

Analytical Method Development: SOP for Stability-Indicating Method for Lyophilized Injections – V 2.0

Standard Operating Procedure for Stability-Indicating Method for Lyophilized Injections in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/277/2025
Supersedes SOP/AMD/277/2022
Page No. Page 1 of 13
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To define a validated analytical procedure for the development of a stability-indicating method (SIM) for lyophilized injectable formulations, capable of distinguishing the active pharmaceutical ingredient (API)

from its degradation products under forced degradation and stability conditions.

2. Scope

This SOP applies to Analytical Method Development and Quality Control departments responsible for establishing and validating stability-indicating methods for lyophilized injections as part of regulatory submissions and ongoing stability programs.

3. Responsibilities

  • Analytical Scientist: Develops and validates the method, performs forced degradation, and interprets results.
  • Stability Team: Provides samples from various storage conditions for method evaluation.
  • QA Executive: Reviews method development protocol and ensures regulatory compliance.

4. Accountability

The Head of Analytical Method Development is accountable for the suitability, validation, and regulatory acceptance of the SIM developed for lyophilized injectable products.

See also  Analytical Method Development: SOP for Viscosity Method Development Using Brookfield Viscometer - V 2.0

5. Procedure

5.1 Selection of Analytical Technique

  1. HPLC with UV detection is preferred; other options include HPLC-MS or UPLC depending on sensitivity and regulatory requirement.
  2. Select detection wavelength based on UV spectrum of API and degradation products.

5.2 Forced Degradation Studies

  1. Subject the API and lyophilized formulation to stress conditions:
    • Acid hydrolysis (0.1N HCl, 2 hours at 60°C)
    • Alkali hydrolysis (0.1N NaOH, 2 hours at 60°C)
    • Oxidation (3% H2O2, 2 hours at 25°C)
    • Thermal stress (80°C for 24 hours)
    • Photolysis (UV exposure for 24 hours)
  2. Neutralize samples if needed and analyze using preliminary method.

5.3 Method Optimization

  1. Optimize chromatographic conditions to achieve baseline separation of API from all degradation products.
  2. Adjust mobile phase pH, gradient, temperature, and column type (e.g., C18).

5.4 Sample and Standard Preparation

  1. Reconstitute lyophilized powder using sterile WFI as per product instructions.
  2. Prepare standard solution of API at known concentration in diluent.
  3. Filter through 0.22 µm membrane before injection.
See also  Analytical Method Development: SOP for pH Determination of Semi-Solid Formulations - V 2.0

5.5 HPLC Conditions (Typical)

  • Column: C18, 250 mm × 4.6 mm, 5 µm
  • Mobile Phase: Water (pH 3.0 with OPA):Acetonitrile = 65:35 v/v
  • Flow Rate: 1.0 mL/min
  • Detection: 230 nm
  • Injection Volume: 20 µL

5.6 Validation Parameters

  1. Specificity: Degradation peaks must be well resolved from API with purity angle < purity threshold.
  2. Linearity: r² ≥ 0.999 across 50%–150% of target concentration.
  3. Accuracy: 98%–102% recovery at 3 concentration levels.
  4. Precision: RSD ≤ 2.0% for repeatability and intermediate precision.
  5. LOD/LOQ: Established for API and major degradation products.
  6. Robustness: Minor changes in pH, flow rate, and temperature should not affect resolution.

5.7 Acceptance Criteria

  • API peak should be separated with resolution ≥ 2.0 from nearest impurity.
  • No co-elution with excipients or degradation peaks.
  • Peak purity index ≥ 0.999.

6. Abbreviations

  • SIM: Stability Indicating Method
  • HPLC: High Performance Liquid Chromatography
  • LOD: Limit of Detection
  • LOQ: Limit of Quantification
  • WFI: Water for Injection

7. Documents

  1. Stability-Indicating Method Development Log – Annexure-1
  2. Forced Degradation Summary Table – Annexure-2
  3. Validation Report – Annexure-3
See also  Analytical Method Development: SOP for Qualification and Performance Verification of Analytical Balances - V 2.0

8. References

  • ICH Q2(R1): Validation of Analytical Procedures
  • ICH Q1A(R2): Stability Testing of New Drug Substances and Products
  • USP <621>, <1225>, <1086>

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Anita Kulshreshtha Ravi Iyer Sunita Reddy
Designation Stability Chemist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Stability-Indicating Method Development Log

Sample ID Stress Condition Degradation (%) Resolution Status
SIM-277-01 Acid hydrolysis 15% 3.5 Pass

Annexure-2: Forced Degradation Summary Table

Condition Duration Degradation Observed Comments
0.1N NaOH 2 hr @ 60°C 18% Major degradation at 2.8 min

Annexure-3: Validation Report

The developed SIM was validated for a lyophilized cephalosporin formulation. It effectively resolved degradants from API and met all ICH validation criteria. The method is suitable for long-term and accelerated stability studies.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Included Annexure for degradation summary, expanded robustness Annual Review Sunita Reddy
01/05/2022 1.0 Initial Release New SOP QA Head
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: SOP Compliance in Packaging Operations: Best Practices and Case Studies
Next Post: SOP and Electronic Logbook Disconnect: A GMP Compliance Vulnerability

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version